How many institutions held SXTC - China SXT Pharmaceuticals, Inc. - Common stock, $0.08 par value in Q1 2024?

3 institutional investors reported SXTC - China SXT Pharmaceuticals, Inc. - Common stock, $0.08 par value for Q1 2024. Use the holders table for investor-level position and value details.

China SXT Pharmaceuticals, Inc. - Common stock, $0.08 par value (SXTC)

Q: What does CUSIP G2161P140 represent in this 13F holders report?

CUSIP G2161P140 is the security identifier for SXTC - China SXT Pharmaceuticals, Inc. - Common stock, $0.08 par value used to aggregate holder disclosures.

CUSIP: G2161P140

Q1 2024 13F Holders as of 31 Mar 2024

Security type / class: Equity / Common stock, $0.08 par value
Total 13F shares: 2,870
Total 13F value: $3,186
Share change: -6,300
SEC-reported price per share: $1.62
Number of holders: 3
Value change: -$10,232
Number of buys: 1
Number of sells: 1

Security key

G2161P140

Report period

Q1 2024

Institutions

Top holders

SXTC full security history Ownership snapshot Full 13F holder table China SXT Pharmaceuticals, Inc. SEC filings China SXT Pharmaceuticals, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of SXTC - China SXT Pharmaceuticals, Inc. - Common stock, $0.08 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Marex Group Ltd

Disclosed value leader

Marex Group Ltd

Comparable rows

0/5

Latest evidence

31 Dec 2023

13F 3/4/5 Highest disclosed value: $163,933 5 rows are not safely comparable across share classes.

Quick read

Marex Group Ltd has the largest disclosed position value at $163.9K.

0 of 5 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Marex Group Ltd's linked filing trail.

Disclosed position value Top 4

Marex Group Ltd $163.9K

UBS Group AG $25.4K

ACADIAN ASSET MANAGEMENT LLC $10K

Qube Research & Technologies Ltd $12

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-5 of 5 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Marex Group Ltd	13F Company 13F	— class O/S missing	$163,933 41,293 shares	—	31 Dec 2023
UBS Group AG	13F Company 13F	— class O/S missing	$25,440 6,408 shares	—	31 Dec 2023
ACADIAN ASSET MANAGEMENT LLC	13F Company 13F	— class O/S missing	$10,000 2,759 shares	—	31 Dec 2023
Qube Research & Technologies Ltd	13F Company 13F	— class O/S missing	$12 3 shares	—	31 Dec 2023
Feng Felix Zhou	3/4/5 Co-CEO and Director, Director 3/4/5	— class O/S missing	— 4 shares	—	04 Jul 2017

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

2,870

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders

Holder diff

Investor	Q1 2024 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q1 2024 value	Q1 2024 value	Value change	Value Chg %